Government Use of Patents in India: What the Kerala High Court's Ribociclib Ruling Means
IPR Manager Team · 19 Oct 2026
Updated: October 2026
A patent gives its owner the right to stop others from making or selling the invention. That right has limits, and one of the oldest is government use of patents in India under Section 100 of the Patents Act, 1970.
On 28 September 2026, the Kerala High Court gave that power its widest reading yet. It held that the Centre can use a medicine patent to make and sell the drug to needy patients, without the patentee's consent, if the price puts it out of reach.
Several headlines called this compulsory licensing. It is not, and the difference matters for patentees and generic makers alike. This guide explains what the court decided, how Section 100 works, how it compares with the other routes in the Act, and what patent holders should do now.
Quick Answer
- Section 100 lets the Central Government, or anyone it authorises in writing, use a patented invention for the purposes of Government.
- The patentee is paid adequate remuneration, agreed or fixed by the High Court.
- The Kerala High Court (28 September 2026) held this includes making and selling a medicine to needy patients on a non-commercial basis.
- The court left the decision to the Centre, after it collects affordability data. It set no deadline.
- A compulsory licence is different: an applicant asks the Controller under Section 84, at least three years after grant.
Table of Contents
- What the Kerala High Court decided
- How Section 100 works
- Four routes compared
- Compulsory licences in practice
- What patentees should do now
- What it means for patients and generics
- Common mistakes
- Frequently asked questions
What the Kerala High Court Decided
The Kerala High Court held that the Government's power to use a patent under Section 100 extends to manufacturing a patented medicine and selling it to patients on a non-commercial basis. The case is In Re Exorbitant Pricing of Life Saving Patented Medicines (WP(C) No. 18999 of 2022), decided by Justice Harisankar V. Menon (judgment, 2026:KER:74251).
The petition began with a retired bank employee with metastatic breast cancer who had been prescribed Ribociclib. Her petition put the cost at about ₹58,140 for 21 days, and she asked the Centre to act under Section 92 or Section 100. She died while the case was pending, and the court continued it on its own motion with an amicus curiae.
The court read "purposes of Government" broadly. It said the phrase includes the right to vend the patented product on a non-commercial basis (para 27) and "also includes the duty of the Government/State to improve public health" (para 30). It also found, on expert evidence, that a related drug, Palbociclib, is not a substitute.
What the court did not do is just as important:
- It set no deadline for the Centre.
- It did not order the Government to use the patent, grant a licence or start a free-drug scheme.
- It did not decide the Section 92 request.
- It did not set aside the Centre's 2022 order rejecting the original representation.
Instead, the court said the Government must "collate the required data" on affected patients and affordability, decide whether the medicine is affordable, and invoke Section 100 if necessary. Whether to do so is "a policy decision" for the Centre (para 39).
Government Use of Patents in India: How Section 100 Works
Section 100 is a direct power of the Central Government, not a licence granted by the Patent Office. Under Section 100(1), the Centre and any person it authorises in writing may use an invention for the purposes of Government at any time after a patent application is filed or a patent is granted. The power applies "Notwithstanding anything contained in this Act".
Section 99(1) defines that use: an invention is used for Government purposes if it is "made, used, exercised or vended for the purposes of the Central Government, a State Government or a Government undertaking".
The patentee is not left empty-handed. Under Section 100(3), use is on terms agreed with the patentee, before or after the use. If the parties cannot agree, the High Court fixes the terms on a reference under Section 103. The patentee receives "not more than adequate remuneration", taking into account the economic value of the use.
The Government must also tell the patentee about the use as soon as practicable under Section 100(5), except in a national emergency, extreme urgency or non-commercial use. The patentee can ask for reasonable information about the extent of the use.
Four Routes Compared: Section 84, 92, 100 and 102
The Patents Act gives four ways to use a patented invention without the patentee's consent, and each has a different trigger, decision-maker and payment rule. This table, drawn from the text of the Act, sets them side by side.
| Section 84: compulsory licence | Section 92: notified licence | Section 100: government use | Section 102: acquisition | |
|---|---|---|---|---|
| Who acts | Any interested person applies to the Controller | Centre notifies; Controller grants to applicants | Centre, or a person it authorises in writing | Centre |
| When | After 3 years from grant | National emergency, extreme urgency, or public non-commercial use | Any time after filing or grant | When necessary for a public purpose |
| Grounds or test | Public needs not met; not available at a reasonably affordable price; not worked in India | Declared by Gazette notification | Use for the purposes of Government | Public purpose |
| Prior licence attempt | Applicant's efforts to obtain a licence are considered; "reasonable period" ordinarily up to 6 months | Section 87 procedure not applied | Not required | Not required |
| Notice to patentee | Through the application process | Informed by the Controller | As soon as practicable (exceptions apply) | Notified of the acquisition |
| Payment | Royalty set in the licence | Royalty set in the licence | Adequate remuneration, agreed or fixed by the High Court | Compensation, agreed or fixed by the High Court |
Sources: Section 84, Section 92, Section 100 and Section 102 of the Patents Act, 1970.
Under Section 102, compensation looks at the cost of the invention, the remaining term and the use made of it. A patent's remaining life therefore feeds directly into its value; our free patent term calculator gives the expiry date from the filing date.
💡 Pro Tip: Section 92(3) names public health crises such as HIV/AIDS, tuberculosis and malaria. A Section 92 notification removes the usual compulsory-licence procedure, which is why it is often the faster route in an emergency.
Compulsory Licences in Practice: The Natco Precedent
India's best-known compulsory licence shows how Section 84 works in practice. On 9 March 2012, the Controller granted Natco Pharma a licence for Bayer's patented cancer drug sorafenib tosylate, sold as Nexavar. The royalty was set at 6% of net sales and raised to 7% by the Intellectual Property Appellate Board on 4 March 2013.
The Bombay High Court dismissed Bayer's challenge on 15 July 2014 in Bayer Corporation v. Union of India (WP No. 1323 of 2013), upholding both orders (judgment).
The Kerala ruling points to a different path. A Section 84 licence depends on a private applicant, a three-year wait after grant and a contested hearing. Section 100, on the Kerala reading, lets the Centre act itself, after filing or grant, without asking the Controller.
What Patentees Should Do Now
Patent holders, especially in pharmaceuticals, should prepare for a Government that may now look at Section 100 when prices are challenged. The ruling gives the Centre a data-led test, so patentees benefit from having their own data ready.
- Know your price position. The court asked the Centre to collect data on patients affected and affordability. Have your pricing, access programmes and supply figures documented.
- Track the three-year mark. Section 84 applications open three years after grant. Note that date for every product patent, alongside renewal dates.
- Keep a licensing record. Under Section 84(6), the Controller looks at whether the applicant tried to get a licence on reasonable terms. Keep every licence request and reply on file.
- Know your remuneration case. If the Government uses the patent, Section 100(3) ties payment to the economic value of the use. Your development costs and sales data form the basis of that claim. For a sense of what the early filing stages cost, see our breakdown of patent filing costs in India.
- Watch for notices. Section 100(5) requires the Government to inform you of use, with exceptions. Keep your address for service current.
For agents managing a portfolio of product patents, the grant dates, three-year marks and renewal dates multiply quickly. IPR Manager's deadline tracking records these per matter, so the dates that open a patent to challenge are visible alongside the ones that keep it alive.
What It Means for Patients, Generics and Policy
For patients, the ruling confirms a legal route to cheaper medicines but does not deliver one. Nothing changes until the Centre gathers data and decides to act.
For generic manufacturers, Section 100 allows use by "any person authorised in writing" by the Government. That opens the possibility of supplying a Government programme under a Section 100 authorisation, rather than applying for a compulsory licence.
For policymakers, the court framed the choice as a balance. It noted that patent protection is needed to encourage registration of inventions, while urging that no patient be refused treatment for financial reasons.
Common Mistakes
- Calling Section 100 a compulsory licence. The Controller does not grant it; the Centre exercises it.
- Assuming the patentee gets nothing. Section 100(3) requires adequate remuneration.
- Reading the ruling as an order. The court set no deadline and issued no direction to use the patent.
- Forgetting the three-year rule. Section 84 applications cannot be made in the first three years after grant.
- Keeping licence correspondence in personal inboxes. Evidence of licence negotiations matters under Section 84(6). Store it with the case file; a matter-level system such as IPR Manager keeps it in one place.
Frequently Asked Questions
What is government use of a patent under Section 100?
Section 100 of the Patents Act, 1970 allows the Central Government, and any person it authorises in writing, to use an invention for the purposes of Government after a patent application is filed or a patent is granted. Use for Government purposes means the invention is made, used, exercised or vended for the Central Government, a State Government or a Government undertaking.
Is Section 100 the same as a compulsory licence?
No. A compulsory licence under Section 84 is granted by the Controller to an interested person who applies at least three years after grant. Section 92 licences follow a Central Government notification in an emergency. Section 100 is the Government's own power to use the invention, with no application to the Controller.
Does the patentee get paid when the Government uses a patent?
Yes. Under Section 100(3), use is on terms agreed with the patentee before or after the use, or, if they cannot agree, terms fixed by the High Court on a reference under Section 103. The patentee is paid not more than adequate remuneration, considering the economic value of the use.
What did the Kerala High Court decide in the Ribociclib case?
On 28 September 2026, the Kerala High Court held that Section 100 includes the Government's right to manufacture a patented medicine and sell it to needy patients on a non-commercial basis. It said the Centre must collect data on affordability and decide whether to invoke Section 100. It set no deadline and did not order the Government to act.
When can someone apply for a compulsory licence in India?
Under Section 84, any interested person can apply after three years from the date of grant, on grounds that the public's reasonable requirements are not met, the invention is not available at a reasonably affordable price, or it is not worked in India. The applicant should first try to obtain a licence on reasonable terms, ordinarily for up to six months.
Has India granted a compulsory licence before?
Yes. On 9 March 2012, the Controller granted Natco Pharma a compulsory licence for Bayer's sorafenib tosylate under Section 84, with a 6% royalty later raised to 7%. The Bombay High Court upheld the licence on 15 July 2014.
Final Thoughts
Government use of patents in India was always on the statute book. The Kerala High Court has now read it to cover making and selling medicines to patients, and has asked the Centre to decide, with data, when to use it.
For patentees, the practical response is preparation rather than alarm: know your price and access position, keep licensing records, and track the dates that matter. For a refresher on what a granted patent gives you in the first place, see our guide on how a patent is granted in India.
Related reading
- How a patent is granted in India: the filing-to-grant process.
- Patent filing costs in India: fees from filing to grant.
- Patent term calculator: work out when a patent expires.
References
- Kerala High Court, In Re Exorbitant Pricing of Life Saving Patented Medicines, WP(C) No. 18999 of 2022, 2026:KER:74251, 28 September 2026.
- IP India, Patents Act, 1970, Section 100, accessed October 2026.
- IP India, Patents Act, 1970, Section 99, accessed October 2026.
- IP India, Patents Act, 1970, Section 84, accessed October 2026.
- IP India, Patents Act, 1970, Section 92, accessed October 2026.
- IP India, Patents Act, 1970, Section 102, accessed October 2026.
- Bombay High Court, Bayer Corporation v. Union of India, WP No. 1323 of 2013, 15 July 2014.
- LiveLaw, Kerala High Court on Section 100 and patented drugs, 28 September 2026.
This article is general information, not legal advice. For decisions on a specific application, consult a registered patent agent.
This article was reviewed by Kavita Singla, a registered patent agent with 7 years of Indian IP practice.